Core Viewpoint - Tianyuan Medical (00557) announced that Tianyuan Manganese informed the company about an internal equity restructuring scheduled for December 17, 2025, involving a share transfer agreement between Ningxia Tianyuan Group and Ningxia Tianyuan Co., which will result in the transfer of 100% equity of Tianyuan Manganese to Ningxia Tianyuan Co. [1] Group 1 - The restructuring was completed on the same day it was announced, December 17, 2025 [1] - Prior to the restructuring, Tianyuan Manganese directly held approximately 66.69% of the total issued shares of the company [1] - Tianyuan Manganese was wholly owned by Ningxia Tianyuan Group, which is directly held by Mr. Jia, who owns approximately 99.99% [1] Group 2 - After the restructuring, Tianyuan Manganese is directly held 100% by Ningxia Tianyuan Co., while Ningxia Tianyuan Co. remains wholly owned by Ningxia Tianyuan Group, which is also directly held by Mr. Jia [1] - Tianyuan Manganese continues to hold approximately 66.69% of the total issued shares of the company [1] - The board believes that the restructuring will not have any significant impact on the management and operations of the company [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 自願公佈 控股股東股權架構變動 本公佈由本公司自願作出。 重組 本公司獲天元錳業告知，於二零二五年十二月十七日，由於天元錳業內部股權 重組，寧夏天元集團與寧夏天元股份訂立一份股權劃轉協議，據此，寧夏天元集 團將其持有的天元錳業100%股權無償劃轉予寧夏天元股份（「該重組」）。本公司 進一步獲告知，該重組已於同日（即二零二五年十二月十七日）完成。 收購守則之涵義 由於寧夏天元股份於該重組完成後間接收購本公司已發行股份總數約66.69%， 寧夏天元股份已申請，且執行人員已授出豁免，據此，根據收購守則第26.1條註 釋6(a)，寧夏天元股份無需因該重組而就本公司所有已發行股份提出全面要約。 釋義 於本公佈內，除文義另有所指外，下列詞彙具有以下涵義： ...

Group 1: Optical Communication Sector - The optical communication concept is experiencing a strong rebound, with companies like LIGONG Optical Science (300557) hitting the daily limit up of "20cm" [2] - Tongding Interconnection has seen a rise with two consecutive trading days of gains, while other companies such as Changfei Optical Fiber, Fenghuo Communication, and Hengtong Optic-Electric are also following suit [2] Group 2: Market Performance - The A-share market is showing overall positive performance, with all three major indices rising and a total market turnover of 12,860 billion, with over 4,600 stocks increasing in value [8] - The dairy industry concept is also gaining strength, with companies like Huanlejia reaching a "20cm" limit up and an increase of over 18% at the time of reporting [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | 本月底法定/ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | 本月底法定/ ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | 本月底法定/註冊股本總額： HKD 2,720,615,042 FF301 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2 ...

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 (incorporated in the Cayman Islands with limited liability) 於開曼群島註冊成立的有限責任公司 ) (Stock Code 股份代號：557 ) N O T I F I C AT I O N L E T T E R 29 September 2025 Dear Non-Registered Shareholder(s), China Tian Yuan Healthcare Group Limited (the "Company") – Notice of Publication of Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on t ...

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 (incorporated in the Cayman Islands with limited liability) 於開曼群島註冊成立的有限責任公司 ) (Stock Code 股份代號：557 ) N O T I F I C AT I O N L E T T E R Dear Registered Shareholders, 29 September 2025 Solicitation of electronic contact details China Tian Yuan Healthcare Group Limited (the "Company") – Notice of Publication of Interim Report (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chi ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 8,436,000, a decrease of 43.5% compared to HKD 14,861,000 for the same period in 2024[4] - Gross profit for the period was HKD 8,133,000, down 17.5% from HKD 9,858,000 year-on-year[4] - The company reported a loss of HKD 5,538,000 for the six months ended June 30, 2025, compared to a loss of HKD 8,983,000 in the same period of 2024, representing a 38.5% improvement[5] - The net loss attributable to equity holders of the company was HKD 3,065,000, compared to HKD 5,606,000 in the previous year, indicating a 45.4% reduction in losses[4] - Total comprehensive loss for the period was HKD 3,451,000, a decrease from HKD 8,390,000 in the prior year, reflecting a 58.8% improvement[5] - Total revenue for the six months ended June 30, 2025, was HKD 8,735,000, compared to HKD 15,126,000 for the same period in 2024, representing a decrease of approximately 42.5%[21] - The net loss for the six months ended June 30, 2025, was HKD 3,065,000, compared to a net loss of HKD 5,606,000 for the same period in 2024, indicating an improvement of about 45.4%[33] - The net loss for the period was approximately HKD 5,500,000, an improvement from a net loss of approximately HKD 9,000,000 in the same period last year, with the attributable loss to equity holders of the company being approximately HKD 3,100,000 compared to HKD 5,600,000 last year[52] Assets and Liabilities - Non-current assets as of June 30, 2025, totaled HKD 85,705,000, slightly down from HKD 86,147,000 at the end of 2024[7] - Current assets increased to HKD 177,408,000 from HKD 174,787,000, showing a growth of 1.5%[7] - The total equity attributable to equity holders of the company was HKD 193,984,000, a slight decrease from HKD 194,682,000 at the end of 2024[8] - Reportable segment assets increased to HKD 261,469,000 as of June 30, 2025, from HKD 259,290,000 as of December 31, 2024, reflecting a growth of about 0.8%[22] - Reportable segment liabilities rose to HKD 90,450,000 as of June 30, 2025, compared to HKD 84,820,000 as of December 31, 2024, an increase of approximately 6.1%[22] - Accounts receivable as of June 30, 2025, amounted to HKD 6,199,000, down from HKD 7,960,000 as of December 31, 2024, reflecting a decrease of approximately 22%[36] - Accounts payable rose to HKD 5,389,000 as of June 30, 2025, from HKD 3,685,000 as of December 31, 2024, indicating an increase of about 46%[44] Cash Flow and Liquidity - The company's cash and cash equivalents stood at HKD 26,472,000, up from HKD 24,468,000, representing an 8.2% increase[7] - Operating cash flow for the six months ended June 30, 2025, was HKD 4,757,000, an increase of 35.5% compared to HKD 3,508,000 for the same period in 2024[12] - Cash and cash equivalents increased by HKD 2,158,000 for the six months ended June 30, 2025, compared to a decrease of HKD 86,000 in the same period of 2024[13] - Total cash and cash equivalents as of June 30, 2025, amounted to HKD 26,472,000, up from HKD 20,793,000 as of June 30, 2024, representing a growth of 27.0%[13] - The financing activities cash outflow for the six months ended June 30, 2025, was HKD 2,599,000, a decrease of 27.7% from HKD 3,594,000 in the same period of 2024[12] - As of June 30, 2025, the company reported a net cash position of HKD 26,500,000, resulting in a debt-to-asset ratio of zero[76] Segment Performance - The company operates in four reportable segments: Investment Holding, Medical, Lending and Related Services, and Hotel, with each segment contributing to overall revenue generation[18][20] - The Medical segment generates revenue primarily through procurement, marketing, and management services for the healthcare industry, with operations in Hong Kong, South Korea, and China[18] - The Lending and Related Services segment focuses on providing loans and earning interest, with activities primarily in China and Hong Kong[20] - Medical revenue for the six months ended June 30, 2025, was HKD 522,000, down from HKD 6,714,000 in 2024, a decline of about 92.2%[23] - Interest income from third-party loans was HKD 7,914,000 for the six months ended June 30, 2025, compared to HKD 8,147,000 in 2024, a decrease of approximately 2.9%[24] - The medical segment recorded zero revenue and a net loss of approximately HKD 4,200,000, down from revenue of approximately HKD 5,900,000 and a net loss of HKD 6,300,000 in the same period last year, mainly due to business suspension and renovations[54] - The lending and related business segment reported third-party loan interest income of HKD 7,900,000, down from HKD 8,100,000 in the same period last year, but recorded a reversal of expected credit losses of approximately HKD 2,500,000[55] Credit Quality and Provisions - The company reported an increase in expected credit loss reversal to HKD 2,496,000 from HKD 399,000 in the previous year, indicating a significant improvement in credit quality[4] - The provision for expected credit losses on accounts receivable decreased from HKD 4,021,000 to HKD 3,029,000, a reduction of about 25%[36] - The company has provided loans to third parties totaling HKD 187,668,000, with an expected credit loss provision of HKD 68,315,000, resulting in net loans of HKD 119,353,000[39] Strategic Developments - The company actively developed new skincare products during the period, indicating a strategic focus on expanding its medical segment[53] - The company plans to further develop and expand its core business in the medical and aesthetic sectors, particularly in China and other Asian markets, anticipating growth in consumer spending in the medical beauty industry[57] - The company has launched the DA mask, a hyaluronic acid mask designed for immediate post-procedure use in medical beauty settings, and will promote it through Shanghai Hospital's customer channels[58] - The brand PoAoyan aims to provide a full cycle of skincare products for post-aesthetic treatment, targeting existing customers of Shanghai Hospital to convert them into seed users[58] - The company has received the Bazaar Beauty Annual Award in 2024, enhancing the brand's influence and online promotion capabilities, with plans to increase market presence and share throughout the year[59] - The company will continue its lending and related businesses, adopting a cautious approach to credit assessment due to the adverse effects of US-China trade tensions[60] - The company intends to hold various securities and will monitor and adjust its investment portfolio according to economic conditions, aiming to improve investment returns[61] - The management is actively seeking new business opportunities to diversify and increase revenue sources while developing existing operations[62] Governance and Compliance - The company has not adopted any new accounting standards or amendments that would significantly impact its financial position or performance during the reporting period[17] - The financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards, ensuring compliance with applicable disclosure requirements[15] - The management team evaluates segment performance based on operating profit, which includes revenue and expenses allocated to each reportable segment[19] - The company has adopted the "Standard Code for Securities Transactions by Directors" and confirmed compliance throughout the reporting period[72] - No share option schemes are in place as of the reporting date[80] - Major shareholders include Dong Jufeng and Jia Tianjiang, each holding approximately 66.69% of the issued share capital[82] - The company confirms that there are no significant discrepancies between the existing information and the data disclosed in the 2024 annual report[84] - The board of directors and senior management guarantee the authenticity, accuracy, and completeness of the mid-term financial report for 2025, assuming legal responsibility for any misstatements or omissions[84] Legal Matters - The company is currently involved in legal proceedings related to loan recoveries, with a court ruling expected by January 24, 2026[42] - The company initiated bankruptcy proceedings against Mr. Li on July 2, 2021, with a total claim amounting to approximately $12,000,000, including unpaid interest as of the bankruptcy order date[70] - The trustee accepted a claim of approximately HKD 95,000,000 from the company on November 25, 2022, related to the bankruptcy proceedings[70] Employee and Operational Costs - The total employee cost for the six months ending June 30, 2025, was HKD 3,400,000, covering salaries, wages, and other benefits for 31 employees[79] - As of June 30, 2025, the company had no bank borrowings and no pledged assets[76][77] - The company has not engaged in any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the reporting period[74] - There were no major contingent liabilities reported as of June 30, 2025[75]

致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 FF301 呈交日期: 2025年9月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | 1 | HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | 1 | HKD | | 2,720,615,042 | 第 ...